Press Releases XOMA Corporation

Equities

XOMA

US98419J2069

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
24.2 ^USD	-1.31%		-6.27%	+30.81%

04-30	XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	CI
04-29	Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

XOMA : 2024 Letter to Shareholders	08:15am	PU
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	04-30	AQ
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	04-25	AQ
XOMA : Acquisition/Asset Disposal - Form 8-K	04-03	PU
XOMA Corporation Announces Closing of Tender Offer	04-03	AQ
XOMA Declares Quarterly Preferred Stock Dividends	03-21	AQ
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	03-19	AQ
Xoma: Q4 Earnings Snapshot	03-08	AQ
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	03-08	AQ
XOMA to Present at Upcoming Investor Conferences in March	02-28	AQ
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	02-19	AQ
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	02-16	PR
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	02-16	AQ
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition	01-19	AQ
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition	01-18	AQ
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C Results in XOMA Making a $1 Million Milestone Payment to LadRx	01-12	AQ
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx	01-11	AQ
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors	01-08	AQ
XOMA Announces Stock Repurchase Program of up to $50 Million	01-02	AQ
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties	12-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases XOMA Corporation

Equities

XOMA

US98419J2069

Press Releases

Filters